Unique pediatric evaluation targets relevant autoimmune/CNS antibodies - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers...
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
Melanoma panel provides more tumor information - Insights
In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.
Comprehensive panel boosts GIST diagnosis sensitivity - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.
Answers From the Lab - Insights
A Mayo Clinic podcast sharing knowledge and advances in testing, laboratory science, and the people who make it all happen behind the scenes. Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or...
West Nile virus [Test in Focus] - Insights
Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.
Including comprehensive panels and medication targeted assays, Mayo Clinic Laboratories pharmacogenomic testing focuses on clinically actionable genes and enables the detection of more alleles than other testing.
GFAP: Novel Test for a Newly Identified Meningoencephalomyelitis - Insights
Mayo Clinic Laboratories is the only laboratory in the world to offer testing for a novel form of autoimmune meningoencephalomyelitis. Known as autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, the condition was identified...
Medication-targeted testing - Insights
Learn more about how medication targeted testing at Mayo Clinic Laboratories can assist in treatment optimization for medication with established pharmacogenomic associations.
Novel biomarkers added to movement disorders profile - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.